RUNX3 and rectal cancer: In 2012, Jo and colleagues used methylation specific PCR to examine a panel of 5 CIMP markers (i.e., CACNA1G, IGF2, NEUROG1, RUNX3, and SOCS1) in rectal cancer patients receiving 5-FU-based neoadjuvant chemoradiation [79].